Granules India seeks first-to-file status for Ruxolitinib ER Tablets

Granules India has submitted a Paragraph IV certification for its Abbreviated New Drug Application (ANDA) for Ruxolitinib Extended-Release Tablets, seeking sole first-to-file status.